Vascular KCNQ potassium channels as novel targets for the control of mesenteric artery constriction by vasopressin, based on studies in single cells, pressurized arteries, and in vivo measurements of mesenteric vascular resistance

Journal of Pharmacology and Experimental Therapeutics

Volumn 325, Issue 2, 2008, Pages 475-483

  Mackie, Alexander R ^a   Brueggemann, Lioubov I ^a   Henderson, Kyle K ^b   Shiels, Aaron J ^b,c   Cribbs, Leanne L ^b   Scrogin, Karie E ^a   Byron, Kenneth L ^a,d  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

^c UNIVERSITY OF ILLINOIS   (United States)

^d LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

10,10 BIS(4 PYRIDINYLMETHYL) 9(10H) ANTHRACENONE; CALPHOSTIN; LINOPIRDINE; POTASSIUM CHANNEL KCNQ; POTASSIUM CHANNEL KCNQ1; POTASSIUM CHANNEL KCNQ3; POTASSIUM CHANNEL KCNQ5; UNCLASSIFIED DRUG; VASOPRESSIN; AMINOPYRIDINE DERIVATIVE; CALCIUM CHANNEL L TYPE; FLUPIRTINE; INDOLE DERIVATIVE; POTASSIUM CHANNEL BLOCKING AGENT; PROTEIN KINASE C; PYRIDINE DERIVATIVE; VASOCONSTRICTOR AGENT; VASOPRESSIN DERIVATIVE;

ANIMAL EXPERIMENT; ARTERY CONSTRICTION; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG INHIBITION; ELECTROPHYSIOLOGY; IN VIVO STUDY; MALE; MEMBRANE DEPOLARIZATION; MESENTERIC ARTERY; NONHUMAN; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VASCULAR RESISTANCE; VASOCONSTRICTION; ANIMAL; BLOOD PRESSURE; CYTOLOGY; DRUG ANTAGONISM; DRUG POTENTIATION; HEART RATE; MUSCLE CELL; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

AMINOPYRIDINES; ANIMALS; BLOOD PRESSURE; CALCIUM CHANNELS, L-TYPE; HEART RATE; INDOLES; KCNQ POTASSIUM CHANNELS; MALE; MESENTERIC ARTERIES; MUSCLE CELLS; POTASSIUM CHANNEL BLOCKERS; PROTEIN KINASE C; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; VASCULAR RESISTANCE; VASOCONSTRICTOR AGENTS; VASOPRESSINS;

EID: 42449127582     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.135764     Document Type: Article

References (47)

1. Altura BM (1975) Dose-response relationships for arginine vasopressin and synthetic analogs on three types of rat blood vessels: possible evidence for regional differences in vasopressin receptor sites within a mammal. J Pharmacol Exp Ther 193:413-423.
2. Altura BM (1976) Microcirculatory approach to the treatment of circulatory shock with a new analog of vasopressin, (2-phenylalanine, 8-ornithine)vasopressin. J Pharmacol Exp Ther 198:187-196.
3. Banks RO, Gallavan RH Jr, Zinner MH, Bulkley GB, Harper SL, Granger DN, and Jacobson ED (1985) Vasoactive agents in control of the mesenteric circulation. Fed Proc 44:2743-2749.
4. Barrett LK, Singer M, and Clapp LH (2007) Vasopressin: mechanisms of action on the vasculature in health and in septic shock. Crit Care Med 35:33-40.
5. + channels are expressed in mesenteric artery smooth muscle cells. Am J Physiol Heart Circ Physiol 289:H137-H145.
6. Bosma MM and Hille B (1989) Protein kinase C is not necessary for peptide-induced suppression of M current or for desensitization of the peptide receptors. Proc Natl Acad Sci U S A 86:2943-2947.
7. 2 hydrolysis: significance for receptor-mediated inhibition. J Physiol 582:917-925.
8. 2+ entry in vascular smooth muscle cells. J Pharmacol Exp Ther 317:488-499.
9. Brueggemann LI, Moran CJ, Barakat JA, Yeh JZ, Cribbs LL, and Byron KL (2007) Vasopressin stimulates action potential firing by protein kinase C-dependent inhibition of KCNQ5 in A7r5 rat aortic smooth muscle cells. Am J Physiol Heart Circ Physiol 292:H1352-H1363.
10. 2+ spiking activity in A7r5 vascular smooth muscle cells via activation of phospholipase A2. Circ Res 78:813-820.
11. + channels in vascular smooth muscle by phosphorylation. Biochem Cell Biol 74:439-447.
12. Cowley AW Jr, Cushman WC, Quillen EW Jr, Skelton MM, and Langford HG (1981) Vasopressin elevation in essential hypertension and increased responsiveness to sodium intake. Hypertension 3:I93-I100.
13. Cox RH (2005) Molecular determinants of voltage-gated potassium currents in vascular smooth muscle. Cell Biochem Biophys 42:167-195.
14. 2+ stores in rat sympathetic neurons. Proc Natl Acad Sci U S A 95:7151-7156.
15. Delgado TJ, Arbab MA, Warberg J, and Svendgaard NA (1988) The role of vasopressin in acute cerebral vasospasm. Effect on spasm of a vasopressin antagonist or vasopressin antiserum. J Neurosurg 68:266-273.
16. Delmas P and Brown DA (2005) Pathways modulating neural KCNQ/M (Kv7) potassium channels. Nat Rev Neurosci 6:850-862.
17. Doyle VM and Ruegg UT (1985) Vasopressin induced production of inositol trisphosphate and calcium efflux in a smooth muscle cell line. Biochem Biophys Res Commun 131:469-476.
18. Dumont E and Lamontagne D (1995) No role of ATP-sensitive potassium channels in the vasoconstriction produced by vasopressin. J Vasc Res 32:138-142.
19. Fenger-Gron J, Mulvany MJ, and Christensen KL (1995) Mesenteric blood pressure profile of conscious, freely moving rats. J Physiol 488:753-760.
20. Henderson KK and Byron KL (2007) Vasopressin-induced vasoconstriction: two concentration-dependent signaling pathways. J Appl Physiol 102:1402-1409.
21. Herrmann WM, Kern U, and Aigner M (1987) On the adverse reactions and efficacy of long-term treatment with flupirtine: preliminary results of an ongoing twelve-month study with 200 patients suffering from chronic pain states in arthrosis or arthritis. Postgrad Med J 63(Suppl 3):87-103.
22. Holmes CL, Patel BM, Russell JA, and Walley KR (2001) Physiology of vasopressin relevant to management of septic shock. Chest 120:989-1002.
23. Hoshi N, Zhang JS, Omaki M, Takeuchi T, Yokoyama S, Wanaverbecq N, Langeberg LK, Yoneda Y, Scott JD, Brown DA, et al. (2003) AKAP150 signaling complex promotes suppression of the M-current by muscarinic agonists. Nat Neurosci 6:564-571.
24. Jackson WF (2005) Potassium channels in the peripheral microcirculation. Microcirculation 12:113-127.
25. Jentsch TJ (2000) Neuronal KCNQ potassium channels: physiology and role in disease. Nat Rev Neurosci 1:21-30.
26. Joshi S, Balan P, and Gurney AM (2006) Pulmonary vasoconstrictor action of KCNQ potassium channel blockers. Respir Res 7:31.
27. Ma X, Bielefeldt K, Tan ZY, Whiteis CA, Snitsarev V, Abboud FM, and Chapleau MW (2006) Dual mechanisms of angiotensin-induced activation of mouse sympathetic neurones. J Physiol 573:45-63.
28. 2+ concentration in insulin-secreting cells. EMBO J 8:3595-3599.
29. Munro G and Dalby-Brown W (2007) K(v)7 (KCNQ) channel modulators and neuropathic pain. J Med Chem 50:2576-2582.
30. Nakajo K and Kubo Y (2005) Protein kinase C shifts the voltage dependence of KCNQ/M channels expressed in Xenopus oocytes. J Physiol 569:59-74.
31. Nakamura T, Funayama H, Yoshimura A, Tsuruya Y, Saito M, Kawakami M, and Ishikawa SE (2006) Possible vascular role of increased plasma arginine vasopressin in congestive heart failure. Int J Cardiol 106:191-195.
32. Nelson MT and Quayle JM (1995) Physiological roles and properties of potassium channels in arterial smooth muscle. Am J Physiol Cell Physiol 268:C799-C822.
33. Ohya S, Asakura K, Muraki K, Watanabe M, and Imaizumi Y (2002) Molecular and functional characterization of ERG, KCNQ, and KCNE subtypes in rat stomach smooth muscle. Am J Physiol Gastrointest Liver Physiol 282:G277-G287.
34. Ohya S, Sergeant GP, Greenwood IA, and Horowitz B (2003) Molecular variants of KCNQ channels expressed in murine portal vein myocytes: a role in delayed rectifier current. Circ Res 92:1016-1023.
35. Passmore GM, Selyanko AA, Mistry M, Al-Qatari M, Marsh SJ, Matthews EA, Dickenson AH, Brown TA, Burbidge SA, Main M, et al. (2003) KCNQ/M currents in sensory neurons: significance for pain therapy. J Neurosci 23:7227-7236.
36. Rogawski MA (2006) Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Res 69:273-294.
37. Rubart M, Patlak JB, and Nelson MT (1996) Ca2+ currents in cerebral artery smooth muscle cells of rat at physiological Ca2+ concentrations. J Gen Physiol 107:459-472.
38. + channels in the coronary and renal vascular reactivity to vasopressin in diabetic rats. Eur J Pharmacol 471:35-40.
39. Schwake M, Jentsch TJ, and Friedrich T (2003) A carboxy-terminal domain determines the subunit specificity of KCNQ K+ channel assembly. EMBO Rep 4:76-81.
40. Shi W, Cui N, Shi Y, Zhang X, Yang Y, and Jiang C (2007) Arginine vasopressin inhibits Kir6.1/SUR2B channel and constricts the mesenteric artery via V1a receptor and protein kinase C. Am J Physiol Regul Integr Comp Physiol 293:R191-R199.
41. Surti TS, Huang L, Jan YN, Jan LY, and Cooper EC (2005) Identification by mass spectrometry and functional characterization of two phosphorylation sites of KCNQ2/KCNQ3 channels. Proc Natl Acad Sci U S A 102:17828-17833.
42. Surti TS and Jan LY (2005) A potassium channel, the M-channel, as a therapeutic target. Curr Opin Investig Drugs 6:704-711.
43. Treschan TA and Peters J (2006) The vasopressin system: physiology and clinical strategies. Anesthesiology 105:599-612.
44. +-channel activities of cultured smooth muscle cells from porcine coronary artery. Am J Physiol Heart Circ Physiol 263:H491-H496.
45. + channel genes in mesenteric artery smooth muscle cells. Am J Physiol Gastrointest Liver Physiol 277:G1055-G1063.
46. Yeung SY and Greenwood IA (2005) Electrophysiological and functional effects of the KCNQ channel blocker XE991 on murine portal vein smooth muscle cells. Br J Pharmacol 146:585-595.
47. Yeung SY, Pucovsky V, Moffatt JD, Saldanha L, Schwake M, Ohya S, and Greenwood IA (2007) Molecular expression and pharmacological identification of a role for K(v)7 channels in murine vascular reactivity. Br J Pharmacol 151:758-770.